The pharmacological costs of first-line therapies in unselected advanced colorectal cancer patients: a review of published phase III trials

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter J. Giuliani
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors J. Giuliani1, A. Bonetti2
  • 1Department of Oncology - Az. ULSS 21 di Legnago (VR), Legnago, Italy, /
  • 2U.O. Oncologia, Ospedale Mater Salutis, Legnago, Italy, /

Abstract

The efficacy of chemotherapy of advanced colorectal cancer (CRC) has improved significantly over the last 15 years to the present “bench mark” of 20-24 months. However, these improvements came along with a dramatic increase of drug's costs. In light of the relevant expenses of pharmacological interventions it might be interesting to make a balance between the cost of the new drugs administered and the difference in progression free survival (PFS) in first-line for advanced CRC.